OxiGene regulatory update

OXGN (New York) received notice of allowance for a U.S. patent covering methods of inhibiting or destroying cancer cells with N-substituted benzamide compounds. N-substituted benzamides inhibit the DNA repair activity of tumor cells. The allowed patent covers Sensimide, an N-substituted compound in Phase II/III trials to treat inoperable lung tumors. ...